INTRODUCTION
Breast cancer is a heterogeneous disease with a highly variable clinical course. The discovery of hormone receptor (HR)-positive breast carcinoma was of major prognostic and therapeutic import. 1 However, accurate assessment of the status of estrogen receptor (ER) and progesterone receptor (PR) remains problematic.
The quantitative ligand-binding assay (LBA) was supplanted in the 1990s by immunohistochemistry (IHC). 2, 3 All methodologies are challenged by preanalytic and analytic variability. Preanalytic factors include fixation delay/type/duration, and protocol variations. Analytic factors include intra-/inter-observer variability and cut points with regard to percentage of cells stained and staining intensity. 4 This variability may lead to inappropriate treatment decisions.
Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) by Oncotype DX (Genomic Health Inc [GHI] , Redwood City, CA) assay quantifies gene expression using RNA extracted from fixed, paraffin-embedded tissue. 6 To evaluate the utility of standardized quantitative RT-PCR assessment of ER and PR by Oncotype DX as an alternative to IHC, we compared local and central IHC and central quantitative RT-PCR measurement of ER and PR in breast carcinomas from 776 patients.
PATIENTS AND METHODS

Tumor Samples and Patient Clinical Data
The Eastern Cooperative Oncology Group (ECOG) E2197 study was a prospective, randomized, clinical trial that included 2,872 assessable patients with HR-positive or -negative breast cancer and 0 to 3 positive lymph nodes. There was no relapse rate difference between treatment arms. A case-control sample of 776 patients who did (n ϭ 179) or did not (n ϭ 597) relapse were evaluated by the Oncotype DX assay; all relapses were selected, and a subsample of nonrelapses were controls. Paraffin blocks were reviewed by ECOG and GHI to confirm the presence of greater than 5% carcinoma. Seven samples lacked invasive carcinoma in both tissue microarray (TMA) cores but were assayed by RT-PCR: these results were excluded from the concordance analysis. Histologic subtype and grade (revised Nottingham criteria) were assessed centrally from whole tissue sections by one pathologist (F.L.B.).
Local IHC
The local ER/PR assays were performed and interpreted using local protocols and cut points.
Central IHC
A total of 20 TMA blocks were constructed using two 1.0-mm cores per patient tumor. 8 Sections 4 m in size from TMAs were immunostained using the DakoCytomation EnVisionϩ System (Dako, Carpinteria, CA). After deparaffinization, sections were rehydrated and endogenous peroxidase was blocked with 1% H 2 O 2 in methanol. After pressure-induced epitope retrieval (Biocare Medical Decloaking Chamber, Concord CA; citrate buffer, pH 6.0), sections were incubated with anti-ER antibody (clone 1D5, dilution 1:100; Dako) or anti-PR antibody (clone 636, dilution 1:200; Dako) at room temperature. The reaction was visualized using the EnVisionϩ kit and 3,3Ј-diaminobenzidine as chromogen followed by light counterstaining with hematoxylin. Positive and negative controls were used in each staining run.
TMAs were reviewed centrally and scored visually by two pathologists (S.B. and F.L.B.), blinded to all clinicopathologic data, using the Allred score (AS), a method that semiquantitates the proportion of positive cells (scored on a 0 to 5 scale) and staining intensity (scored on a 0 to 3 scale), with a maximum score of 8 (AS Ͼ 2 was considered positive).
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Sample Preparation and Gene Expression Analysis Using Oncotype DX
Gene expression was quantitated from whole tumor sections by Genomic Health using the Oncotype DX assay.
9 RNA was extracted from three 10-m whole sections or from six 10-m sections when manual microdissection (MMD) was required. MMD of whole sections was performed when tumor was amenable to dissection and constituted less than 50% of the epithelia. After DNase I treatment, total RNA content was measured and absence of DNA contamination verified. Gene-specific reverse transcription was performed, followed by quantitative PCR (TaqMan) in 384-well plates using Prism 7900HT instruments (Applied Biosystems, Foster City, CA). The expression of 16 cancer-related genes, including ER (ESR1) and PR (PGR), were normalized relative to five reference genes (ACTB, GAPDH, GUSB, RPLP, and TFRC); reference normalized expression ranged from 0 to 15 units, where each 1-unit increase reflects approximately a two-fold increase in RNA. Classifications of ER and PR status were based on preestablished cutoff points, 6.5 and 5.5 units, established from three prior studies comparing IHC and RT-PCR.
10,11 Assay variability for each gene from instruments, operators, reagents and day-to-day variation was less than 0.5 units (standard deviation).
Statistical Analysis
Because of the low overall relapse rate in E2197, a case-control design was used to select the study cohort, with relapses sampled more heavily than nonrelapses.
12 Patients were sampled separately within 16 strata formed by the cross-classifications of relapse, HR, axillary nodal, and treatment arm status.
Agreement measures between RT-PCR and IHC include overall concordance, calculated as the number of samples that agree divided by the total number of samples, and statistics (agreement adjusted for chance).
13 Exact 95% CIs for the concordance statistic were calculated with the F distribution method using SAS PROC FREQ (SAS Institute, Cary, NC).
14 Positive agreement was calculated as the number of samples positive by both assays divided by the number of samples positive by the IHC assay. Negative agreement was calculated similarly.
Cox proportional hazards regression using weighted pseudo-likelihood estimation examined the associations between ER expression (IHC and RT-PCR) and relapse-free interval (RFI). 15 RFI was defined as the time from entry on E2197 to the first evidence of breast cancer relapse, defined as invasive breast cancer in local, regional, or distant sites, including the ipsilateral breast, but excluding new primary breast cancers in the opposite breast. Follow-up for relapse was censored at the time of death without relapse, new primary cancer in the opposite breast, or at the time the patient was last evaluated for relapse. Five-year recurrence rates were estimated from the Cox proportional hazards regression models, on the basis of the empirical cumulative hazard estimate of the survival function. Associated 95% CIs were obtained by employing the normal theory approximation to the logarithm of the survival estimates. Analyses of time to relapse were weighted because inferences were for the full E2197 study population. All statistical tests were two sided, and P Ͻ .05 was considered significant.
RESULTS
Patient Characteristics
A total of 776 samples are reported in the analysis of local IHC and central RT-PCR and 769 samples in the analysis of central IHC. Seven samples were nonassessable for central IHC (lack of invasive tumor in both TMA cores). Distributions of patient characteristics and tumor characteristics are in Table A1 (online only).
Distribution of ER and PR
ER and PR by central IHC was bimodal (Table 1 ). Among ERpositive patients, ER and PR by central RT-PCR were both more normally distributed than by central IHC (58% of ER-positive patients and 63% of PR-positive patients had an AS of 7 or 8).
Concordance Between IHC and RT-PCR
ER concordance. Concordance was high between central IHC and central RT-PCR ER status (Table 2) ; positive agreement was 99% (95% CI, 98% to 100%), and negative agreement was 86% (95% CI, 82% to 89%). In the absence of a gold standard, the terms percentage of positive and percentage of negative agreement describe diagnostic accuracy as alternatives to the terms sensitivity and specificity as suggested by the US Food and Drug Administration (FDA).
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The two-by-two table for the local IHC versus central RT-PCR comparison is presented in Table 2 . Positive agreement was 95% (95% CI, 93% to 97%). Negative agreement was 87% (95% CI, 83% to 90%). (Table 3) ; positive agreement was 85% (95% CI, 81% to 88%). Negative agreement was 96% (95% CI, 93% to 98%).
The two-by-two table for the local IHC versus central RT-PCR comparisonispresentedinTable3.Positiveagreementwas86%(95%CI, 81% to 89%), and negative agreement was 89% (95% CI, 86% to 92%).
HR concordance. HR positivity was defined as ER and/or PR positive. Concordance between local IHC, central IHC, and central RT-PCR HR status was high (Table 4) 
ER Expression and Recurrence Rates
To determine the relationship between ER expression and recurrence risk, we performed the primary analysis on all study patients. A subset of patients were ER positive by local IHC, central IHC, and central RT-PCR, and were not known to have received hormonal therapy, either because hormone therapy was not given or because it was not known whether hormone therapy was given (32, 46, and 62, respectively; Table A2 , online only); in a secondary analysis we excluded these patients (Ͻ 15% of the total). Figure 2 shows the relationship between central IHC AS and central RT-PCR for ER, and 5-year recurrence rates for all patients (Fig  2A) and for the subset excluding ER-positive patients who didn't receive hormonal therapy (Fig 2B) . Five-year recurrence rates are Figure 2 have similar shapes; however, the CIs for lower levels of ER by AS are larger than those for lower levels of ER by RT-PCR. For comparison, the relationship between the Oncotype DX recurrence score (RS) and recurrence risk in the subset of ER-positive patients (both node-negative and node-positive patients) was determined (Fig 3) . RS was a significant predictor of recurrence (P Ͻ .0001) and was particularly effective at identifying low-risk patients, as noted by the narrow 95% CI for recurrence rate in patients with RS less than 18. Consistent with prior studies, RS was a significant predictor of recurrence (P ϭ .0016) in the subset of node-negative patients (n ϭ 188).
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ER Expression and RS
The distribution of RS by ER expression (central IHC and central RT-PCR) was explored in ER-positive patients (Fig 4A) . Although correlation between RS and ER expression was modest (correlation ϭ Ϫ0.22 for central IHC and Ϫ0.47 central RT-PCR), there were cases with high ER expression and high RS. Similar results were obtained for node-negative and node-positive patients analyzed separately (data not shown).
Tumor Grade and RS
The distribution of RS by tumor grade was explored in ERpositive patients by both central and local HC tumor grade assessment (n ϭ 404) (Fig 4B) . Although there was a strong association overall between RS and tumor grade (P Ͻ .0001 for both local and central grade), there were discrepancies. Modest agreement in assessment of histologic grade among the local and central pathologists was observed (concordance ϭ 67% [95% CI, 63% to 70%]; weighted ϭ 46%; Table A3 , online only).
DISCUSSION
Accurate and precise measurement of HR status is of therapeutic importance because hormonal therapy reduces the relative risk of recurrence by more than 50% in breast cancer patients with hormonesensitive tumors. 1, 17, 18 New methodologies for HR quantitation should be rigorously compared with the current measurement standard. In this study, there was a high level of concordance for ER, PR, and HR status between local and central IHC and central RT-PCR using the Oncotype DX assay ( Table 2 ). The similar concordance between IHC and RT-PCR, when compared with that observed between the local and central IHC, demonstrates that quantitative RT-PCR using the Oncotype DX assay is an alternative method for determination of HR status.
IHC assessment of ER and PR is recommended by the American Society of Clinical Oncology to guide breast cancer treatment. 19 Unfortunately, interlaboratory variability with IHC assessment of ER/PR is relatively high in clinical practice. Rhodes et al 20 showed that 80% of laboratories demonstrated ER positivity in medium-/highexpressing tumors, but only 37% demonstrated ER positivity in low-expressing tumors.
There is diversity in IHC methodology. Protocol differences such as the use of antigen retrieval and the type of antigen retrieval such as pressure steam, used in this study, versus ambient steam, can contribute to variability. 20 Chromogen enhancers may also be used to increase sensitivity of IHC assays (these were not employed in this study). Antibody differences are important. In a comparison of two ER antibodies, 1D5 and SP1, 8% of tamoxifen-treated patients who were SP1 positive but 1D5 negative were noted to have better clinical outcomes. A recent IHC/RT-PCR comparison study of 607 patients using SP1 showed 96% concordance between SP1 and RT-PCR by Oncotype. 27 Another possible source of bias in this study was the use of two 1.0-mm cores (total area ϭ 3.14 mm unlikely given that many groups have reported that three 0.6-mm cores (total area ϭ 1.13 mm 2 ) are highly concordant with whole tumor sections.
Just as all IHC assays are not the same, nor are all RT-PCR assays the same. Differences in RNA extraction, reverse transcription, PCR protocols and machines, primer/probe selection, and reagent manufacturing can contribute to assay variability. Central lab measurement of ER and PR expression by RT-PCR using Oncotype DX employs a large number of controls and calibrators to enhance precision and reproducibility. Normalization with five reference genes addresses differences in RNA quality stemming from preanalytic factors, 22, 23 such as delay to fixation and duration of fixation.
6, 24 Cronin et al 6, 25 recently documented the operational performance of the standardized Oncotype DX assay: linearity over a more than 2,000-fold RNA concentration range with an average accuracy of 0.3%, coefficients of variation for the assay process below 5.7%, and assay variability contributed by instruments, operators, reagents, and day-to-day variation limited to less than 0.5 expression units (standard deviation). Although the overall concordance for ER status was high in this study, discordances that may be a result of biology (in some cases protein expression and mRNA expression may be truly different due to epigenomic factors) and/or to assay performance issues were observed. There was an imbalance in the distribution of the discordant cases between central IHC and central RT-PCR. IHC ER-negative cases that were RT-PCR positive were observed more commonly than IHC ER-positive cases that were RT-PCR negative. These discordant cases that were IHC ER negative and RT-PCR ER positive showed quantitative ER levels by RT-PCR that ranged from 6.5 to 10.5 expression units (16-fold range). In contrast, those cases that were IHC ER positive but RT-PCR negative all tended to cluster within 2 units (four-fold range) of the RT-PCR cutoff. The relatively low incidence of IHC ER-positive cases that are RT-PCR ER negative in this study is similar to the 2% discordance rate between IHC ER-positive and RT-PCR ER-negative cases seen in over 20,050 reported cases from the GHI Clinical Laboratory.
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In contrast to ER, the discordant PR cases were evenly distributed. The PR discordances are not explained by differences in PRA and PRB expression as the RT-PCR PR primer/probe set identifies both species. Finally, when either ER-positive and/or PR-positive cases were assessed as HR positive, the overall concordance was also high (Ն 90%); nevertheless, between 8% (central IHC) and 12% (local IHC) of samples classified as HR negative by IHC were HR positive by RT-PCR.
Although immunohistochemistry detects protein expression while RT-PCR measures mRNA transcription levels, numerous groups have shown a high degree of concordance between the two, particularly with regard to ER assessment. 6,10,11,27,28 Concordance assessment of HR status examines protein and gene expression as dichotomous variables, as either positive or negative; however, equally important is whether HR biology is dichotomous or continuous.
5,29
The LBA reported ER protein on a continuous scale with a large dynamic range. For IHC the Allred system was developed for semiquantitative ER assessment using a specific protocol and antibody and was superior to LBA. 
Mohsin et al
30 demonstrated the utility of the Allred system with similar success. However, implementation of the AS system in different laboratories may give results that differ from the specific methodology employed in the original Allred studies. As shown, the Oncotype DX RT-PCR measures of ER and PR exhibit a continuous distribution of expression over a 3,000-fold and 1,000-fold range, respectively, for ER and PR. In contrast, using the ER clone 1D5 and PR clone 636 AS tended to be bimodal. 27 The relationship between recurrence risk and ER expression by central IHC and central RT-PCR was explored. Five-year recurrence rate estimates were obtained for all patients, and separately for the ER-positive patients who received chemohormonal therapy. As expected, ER by both central IHC and central RT-PCR were significantly associated with relapse when all patients were included in the analysis (P Ͻ .0001 for both). When the ER-positive subgroup was analyzed, ER expression by central IHC AS was marginally associated with recurrence (P ϭ .091), while ER expression by central RT-PCR was significantly associated with recurrence (P ϭ .014). The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 Oncotype DX study in ER-positive patients treated with placebo or tamoxifen showed that quantitative ER was the best single predictor of tamoxifen benefit (interaction P ϭ .0007). 27 Possibly in this study, where all ER-positive patients received combined chemohormonal therapy, ER is less associated with recurrence risk because chemotherapy benefit was lower in patients with higher ER. 31 In contrast, in this subgroup of ER-positive patients, the RS, which incorporates other biologic pathways beyond ER, was a highly significant predictor of recurrence (P Ͻ .0001).
In summary, this study demonstrated a high level of concordance for ER, PR, and HR between local and central IHC laboratories and central RT-PCR using the Oncotype DX assay. Quantitative RT-PCR using the Oncotype DX assay is an alternative method for determining hormone receptor status. 
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